These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34935933)

  • 1. Treatment goals in familial hypercholesterolaemia-time to consider low-density lipoprotein-cholesterol burden.
    Langslet G; Holven KB; Bogsrud MP
    Eur J Prev Cardiol; 2022 Dec; 29(17):2278-2280. PubMed ID: 34935933
    [No Abstract]   [Full Text] [Related]  

  • 2. Microsomal triglyceride transfer protein inhibitor (lomitapide) efficacy in the treatment of patients with homozygous familial hypercholesterolaemia.
    Kolovou G; Diakoumakou O; Kolovou V; Fountas E; Stratakis S; Zacharis E; Liberopoulos EN; Matsouka F; Tsoutsinos A; Mastorakou I; Katsikas T; Mavrogeni S; Hatzigeorgiou G
    Eur J Prev Cardiol; 2020 Jan; 27(2):157-165. PubMed ID: 31403880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia.
    Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A
    Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and treatment of familial hypercholesterolaemia.
    Hovingh GK; Davidson MH; Kastelein JJ; O'Connor AM
    Eur Heart J; 2013 Apr; 34(13):962-71. PubMed ID: 23416791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Familial hypercholesterolaemia.
    Nair DR; Sharifi M; Al-Rasadi K
    Curr Opin Cardiol; 2014 Jul; 29(4):381-8. PubMed ID: 24870549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia.
    Pirillo A; Catapano AL
    Eur J Prev Cardiol; 2022 May; 29(5):829-831. PubMed ID: 35148370
    [No Abstract]   [Full Text] [Related]  

  • 7. A Belgian consensus strategy to identify familial hypercholesterolaemia in the coronary care unit and its subsequent cascade screening and treatment: BEL-FaHST (The BELgium Familial Hypercholesterolaemia STrategy).
    Descamps OS; Van Caenegem O; Hermans MP; Balligand JL; Beauloye C; Bondue A; Carlier S; Castermans E; Chenot F; Claeys M; De Block C; de Leener A; De Meester A; Demeure F; De Raedt H; Desmet W; Elegeert I; Guillaume M; Hoffer E; Kacenelenbogen R; Lancellotti P; Langlois M; Leone A; Mertens A; Paquot N; Vanakker O; Vanoverschelde JL; Verhaegen A; Vermeersch P; Wallemacq C; Rietzschel E;
    Atherosclerosis; 2018 Oct; 277():369-376. PubMed ID: 30270073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia.
    Cortese C; Marenah CB; Miller NE; Lewis B
    Atherosclerosis; 1982 Sep; 44(3):319-25. PubMed ID: 7150396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic diagnosis of familial hypercholesterolemia in a South European outbreed population: influence of low-density lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol.
    Chaves FJ; Real JT; García-García AB; Civera M; Armengod ME; Ascaso JF; Carmena R
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4926-32. PubMed ID: 11600564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous familial hypercholesterolaemia: New hope for getting patients to goal?
    Stock JK
    Atherosclerosis; 2020 Jul; 304():55-56. PubMed ID: 32534726
    [No Abstract]   [Full Text] [Related]  

  • 11. Very high-risk familial hypercholesterolaemia patients in real life: The remaining gap in achieving the current LDL-C targets despite the use of PCSK9 inhibitors.
    Rallidis LS; Liberopoulos EN; Vlachopoulos C; Skoumas I; Kolovou G; Anastasiou G; Dima I; Tousoulis D; Iliodromitis E
    Atherosclerosis; 2020 Sep; 309():67-69. PubMed ID: 32859385
    [No Abstract]   [Full Text] [Related]  

  • 12. Homozygous familial hypercholesterolaemia: update on management.
    France M
    Paediatr Int Child Health; 2016 Nov; 36(4):243-247. PubMed ID: 27967828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Familial Hypercholesterolemia and Lipoprotein(a): Unraveling the Knot That Binds Them.
    Toth PP
    J Am Coll Cardiol; 2020 Jun; 75(21):2694-2697. PubMed ID: 32466884
    [No Abstract]   [Full Text] [Related]  

  • 14. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment.
    Wiegman A; Gidding SS; Watts GF; Chapman MJ; Ginsberg HN; Cuchel M; Ose L; Averna M; Boileau C; Borén J; Bruckert E; Catapano AL; Defesche JC; Descamps OS; Hegele RA; Hovingh GK; Humphries SE; Kovanen PT; Kuivenhoven JA; Masana L; Nordestgaard BG; Pajukanta P; Parhofer KG; Raal FJ; Ray KK; Santos RD; Stalenhoef AF; Steinhagen-Thiessen E; Stroes ES; Taskinen MR; Tybjærg-Hansen A; Wiklund O;
    Eur Heart J; 2015 Sep; 36(36):2425-37. PubMed ID: 26009596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.
    Mol MJ; Erkelens DW; Gevers Leuven JA; Schouten JA; Stalenhoef AF
    Atherosclerosis; 1988 Feb; 69(2-3):131-7. PubMed ID: 3279966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of phenotypic familial hypercholesterolaemia and elevated lipoprotein(a) in patients with premature coronary artery disease: implications for developing cardiometabolic services.
    Wong RS; Lan NSR; Rankin JM; Bell DA; Dwivedi G
    Coron Artery Dis; 2022 Aug; 33(5):421-423. PubMed ID: 35044334
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of the characteristics at diagnosis and treatment of children with heterozygous familial hypercholesterolaemia (FH) from eight European countries.
    Ramaswami U; Futema M; Bogsrud MP; Holven KB; Roeters van Lennep J; Wiegman A; Descamps OS; Vrablik M; Freiberger T; Dieplinger H; Greber-Platzer S; Hanauer-Mader G; Bourbon M; Drogari E; Humphries SE
    Atherosclerosis; 2020 Jan; 292():178-187. PubMed ID: 31809987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
    Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia.
    Durrington PN; Miller JP
    Atherosclerosis; 1985 May; 55(2):187-94. PubMed ID: 3890872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
    Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
    Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.